In the morning of March 1, Mr. Wang Zhexiong, director of the Medical Device Supervision Department of the National Food and Drug Administration, and his team visited Sino Universal Pharma to understand the situation of Sino Universal Pharma. Members from the Party Group of Fujian Food and Drug Administration, Director of Drug Safety Ms. Zhengchun, Party Secretary of the Market Supervision Bureau of Pingtan Comprehensive Experimental Zone Mr. Wu Yaoquan, Chairman of Fujian Pharmaceutical Group Mr. Huang Lifeng accompanied the visit.

The delegation first visited the exhibition hall where company’s products displayed, and listened to the presentation about Sino Universal Pharma’s history, positioning, industrial layout, corporation culture, sales of approved products, and review progress of applied products. The delegation praised Sino Universal Pharma’s strategy that to combine innovation with generics and to support drug innovation with generics. The delegation also highly praised Sino Universal Pharma’s layout of basing in China and developing to the world.

After that, the delegation came to the drug storage area. The quality-control department reported the GSP management process to the delegation The delegation fully recognized Sino Universal Pharma’s achievements in innovation, high efficiency and low cost. They said that, as the first global one-stop pharmaceutical distribution management service provider in China, Sino Universal Pharma is efficient on industrial layout and accurate on innovation-driven strategy. Sino Universal Pharma will adhere to the international ecological road to build a 3C community of drug life cycle by introducing more high-quality and low-cost drugs from all over the world to benefit more Chinese patients and to contribute to the healthy China.